TVTX Earning Date, Earning Analysis and Earning Prediction
Earning Analysis
Welcome to our in-depth analysis of Travere Therapeutics Inc(TVTX) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of Travere Therapeutics Inc earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Surprise Analysis
Name
EPS
Revenue
Price Reaction
Fiscal Quarter
Earning Date
Time
Estimate
Actual
Surprise%
Estimate
Actual
Surprise%
1D
5D
FY2025Q3
2025-10-30
After Hours
-0.09
0.59
+755.56
106.09M
164.86M
+55.40
+18.58
+13.73
FY2025Q2
2025-08-06
After Hours
-0.28
-0.14
+50.00
100.17M
114.45M
+14.25
-1.91
+0.99
FY2025Q1
2025-05-01
After Hours
-0.39
-0.47
-20.51
76.86M
81.73M
+6.34
+1.88
-2.55
FY2024Q4
2025-02-20
After Hours
-0.58
-0.47
+18.97
72.38M
74.79M
+3.33
-6.79
-12.47
FY2024Q3
2024-10-31
Pre-Market
-0.71
-0.70
+1.41
60.83M
62.90M
+3.40
-1.44
-2.56
FY2024Q2
2024-08-01
-
-0.87
-0.90
-3.45
52.69M
54.12M
+2.71
-3.14
-11.74
FY2024Q1
2024-05-06
-
-0.98
-1.76
-79.59
43.62M
41.37M
-5.14
+4.63
+0.64
FY2023Q4
2024-02-15
-
-1.27
-1.16
+8.66
41.82M
45.06M
+7.76
+5.94
-4.73
FY2023Q3
2023-11-07
-
-1.09
-1.17
-7.34
56.45M
37.10M
-34.29
+8.13
-14.16
FY2023Q2
2023-08-03
-
-1.16
-1.13
+2.59
53.60M
59.70M
+11.37
-2.05
-8.24
TVTX Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, Travere Therapeutics Inc reported performance for FY2025Q3, announced on 2025-10-30. The company achieved an EPS of 0.59, compared to analyst estimates of -0.09 by 755.56% . Revenue for the quarter reached 164.86M compared to expectations of 106.09M by 55.40% .
The stock price reacted with a 18.58% one-day change and a 13.73% five-day change following the earnings release. These movements reflect market reaction in Travere Therapeutics Inc growth trajectory and strategic initiatives.
TVTX Earnings Forecast
Looking ahead, Travere Therapeutics Inc(TVTX) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q4 project quarter revenue of 143.04M and an EPS of 0.22.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Upward by 19.86%, while EPS estimates have been Revise Downward by -440.9%. For the upcoming Q4 2025, revenue estimates have been adjusted Revise Upward by 20.74% . These revisions correlate with a 51.59% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in Travere Therapeutics Inc long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between TVTX's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
Revise Upward
+19.86%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-440.9%
In Past 3 Month
Revenue Estimates for Q4 2025
Revise Upward
+20.74%
In Past 3 Month
Stock Price
Go Up
+51.59%
In Past 3 Month
1Y
3Y
5Y
Currency: USD
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:503.75M
--
EPS Estimate-Annual FY 2025:0.75
—
Stock Price35.85
TVTX Revenue and EPS Performance: A Historical Perspective
Travere Therapeutics Inc revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2025Q3 (2025-10-30,After Hours):
EPS: 0.59 (Actual) vs.-0.09 (Estimate) (755.56%)
Revenue: 164.86M (Actual) vs. 106.09M (Estimate) (55.40%)
Price Reaction:18.58%(1-Day), 13.73%(5-Day)
FY2025Q2 (2025-08-06,After Hours):
EPS: -0.14 (Actual) vs.-0.28 (Estimate) (50.00%)
Revenue: 114.45M (Actual) vs. 100.17M (Estimate) (14.25%)
Price Reaction:-1.91%(1-Day), 0.99%(5-Day)
FY2025Q1 (2025-05-01,After Hours):
EPS: -0.47 (Actual) vs.-0.39 (Estimate) (-20.51%)
Revenue: 81.73M (Actual) vs. 76.86M (Estimate) (6.34%)
Price Reaction:1.88%(1-Day), -2.55%(5-Day)
Earnings Reaction
The chart below shows how TVTX performed 10 days before and after its earnings report, based on data from the past quarters. Typically, TVTX sees a -5.67% change in stock price 10 days leading up to the earnings, and a -4.90% change 10 days following the report. On the earnings day itself, the stock moves by +1.52%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in SEP/2025, the stock changed 18.58% on the day following the earnings release and then changed by 14.30% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
People Also Watch
Frequently Asked Questions
What were the key highlights of TVTX's latest earnings report for FY2025Q3?
TVTX reported its FY2025Q3 earnings on 2025-10-30, showcasing a revenue of 164.86M against an estimate of 106.09M, resulting in a 55.4% surprise. The EPS was 0.59, surpassing the expected -0.09 by 755.56% . The stock experienced a 18.58% price change on the earnings day and a 13.73% change over the next five days, reflecting market reactions to the results.
How did TVTX's stock price react after the FY2025Q3 earnings release?
Following TVTX's FY2025Q3 earnings announcement on 2025-10-30, the stock price moved by 18.58% on the day of the release. Over the subsequent five days, it saw a 13.73% change. Historically, TVTX's stock price tends to shift by an average of -5.67% in the 10 days leading up to earnings and -4.90% in the 10 days following, providing insight into potential market.
What are the revenue and EPS estimates for TVTX for 2025/Q4?
For 2025/Q4, analysts estimate TVTX’s annual revenue to reach 143.04M, while the EPS is projected at 0.22. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 19.86% and EPS estimates Revise Upward by 20.74% over the past three months, indicating analyst expectation in the company’s performance.
How does TVTX's stock price correlate with earnings forecast revisions?
The correlation between TVTX's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 19.86%, while EPS estimates moved Revise Upward by 20.74% . This trend suggests that price dips could present buying opportunities for investors.
What should investors expect from TVTX's next earnings report?
Based on historical trends, TVTX's stock price typically moves by -5.67% in the 10 days before its earnings and -4.90% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 0.22 and revenue of 143.04M.
What is the sentiment in Travere Therapeutics Inc (TVTX) Q3 2025 Earnings Call Summary?
The earnings call highlights strong financial performance and strategic developments. FILSPARI's growth in IgA nephropathy and potential FSGS approval, along with positive REMS adjustments, suggest a positive outlook. The Q&A reveals consistent demand and effective communication strategies. Despite some management vagueness, the overall sentiment is positive, with expectations of revenue growth and strategic expansions. The market reaction is likely positive, considering these factors.
